Loading organizations...
Key people at Wilbe Capital.
Wilbe functions as a venture builder and early-stage investor, supporting scientists and engineers in commercializing their research. The firm provides assistance through intensive 'Build Weeks' programs, proprietary platform access, and initial seed funding. Wilbe also develops physical lab spaces, such as Wilbe Labs in London, furnishing equipped environments for nascent science and biotech startups.
Co-founders Ale Maiano, CEO, and Devika Thapar, COO, established Wilbe in 2020. Their core insight stemmed from observing inadequacies within the prevailing science commercialization ecosystem. They identified a critical need to empower scientists and engineers, enabling them to transition novel research and innovative ideas into impactful solutions.
Wilbe primarily serves deep-tech scientists, academic researchers, and engineering founders at the earliest stages of company formation. Its long-term vision centers on cultivating an environment where scientific discovery directly channels into entrepreneurial success. The firm aspires to be the foremost facilitator for scientist leaders, fostering an ecosystem converting ambitious scientific endeavors into enduring companies.
Wilbe Capital is an investment firm founded in 2020 that focuses on supporting and funding scientists and engineers who are developing breakthrough research and innovative solutions, primarily at the seed stage. The firm’s mission centers on backing technically prepared individuals to turn deep scientific ideas into viable ventures without initially taking equity, emphasizing long-term impact over quick returns. Wilbe Capital invests in sectors such as mobility, mental health, data privacy, and finance, aiming to catalyze transformative technologies that address some of the world’s biggest challenges[1][2][3][4].
The firm was established by a team committed to bridging the gap between scientific research and commercial application, providing access to research infrastructure, market guidance, and funding. This origin story highlights Wilbe’s unique positioning as a “Scientists’ Fund,” dedicated to empowering technically skilled founders who might otherwise lack venture capital support. Early traction includes investments in cutting-edge startups like ExpressionEdits, reflecting a focus on deep tech and science-driven innovation[3][4][5].
Wilbe Capital rides the growing trend of science-driven venture investing, where deep technical expertise and breakthrough research are increasingly recognized as key drivers of innovation. The timing is critical as advances in fields like mobility, mental health technologies, and data privacy create new market opportunities. Wilbe’s focus on early-stage, science-based startups positions it to influence the ecosystem by nurturing ventures that might otherwise struggle to find funding due to their technical complexity and longer development horizons.
Looking ahead, Wilbe Capital is likely to deepen its specialization in science and engineering ventures, potentially expanding its portfolio in emerging fields such as fusion energy and synthetic biology. Trends such as increased demand for sustainable technologies and privacy-focused solutions will shape its investment strategy. Wilbe’s influence may grow as it continues to bridge the gap between academia and industry, helping to commercialize breakthrough research that can redefine markets and create new industries.
By focusing on the intersection of science and venture capital, Wilbe Capital stands out as a catalyst for technically ambitious startups, supporting founders who are solving some of the world’s most complex problems with innovative, research-driven approaches[1][2][3][4][5].
Key people at Wilbe Capital.
Wilbe Capital has 9 tracked investments across 5 companies. The latest tracked deal is $6.7M Pre-Seed in Cyclana Bio in October 2025.
